Capital News

Myasthenia Gravis Market

The Myasthenia Gravis market growth is driven by factors like increase in the prevalence of Myasthenia Gravis, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Myasthenia Gravis market report also offers comprehensive insights into the Myasthenia Gravis market size, share, Myasthenia Gravis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Myasthenia Gravis market size growth forward. 

Some of the key highlights from the Myasthenia Gravis Market Insights Report:

• Several key pharmaceutical companies, including Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Harbour BioMed, Novartis, Takeda, DAS Therapeutics, RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, and others, are developing novel products to improve the Myasthenia Gravis treatment outlook. 
• The total Myasthenia Gravis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Myasthenia Gravis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Myasthenia Gravis Market Landscape

Myasthenia Gravis Overview 

Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ) of the skeletal muscles. The classic presentation is a fluctuating weakness that is more prominent in the afternoon. It usually involves muscles of the eyes, throat, and extremities. The reduced transmission of electrical impulses across the neuromuscular junction due to the formation of autoantibodies against the specific postsynaptic membrane proteins consequently causes muscle weakness. A wide variety of conditions can precipitate MG, such as infections, immunization, surgeries, and drugs. Myasthenia gravis causes a significant number of complications. These include myasthenic crisis, an acute respiratory paralysis that requires intensive care, as well as adverse events due to long term medication treatment like opportunistic infections and lymphoproliferative malignancies. A complete understanding of the pathophysiologic mechanisms, clinical manifestations, treatment strategies, and complications of myasthenia gravis is necessary for better patient care and outcomes.

Do you know the treatment paradigms for different countries? Download our Myasthenia Gravis Market Sample Report

Recent Breakthrough in the Myasthenia Gravis Market

FDA Approves Rystiggo for Myasthenia Gravis: People with myasthenia gravis now have a new treatment option that may offer both better and quicker symptom improvement and less discomfort when having the drug administered. On June 27, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients with either of the two most common subtypes of the disease, anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive MG, according to a press release from UCB, the manufacturer of the drug. 

Myasthenia Gravis Epidemiology Segmentation 

DelveInsight’s Myasthenia Gravis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Myasthenia Gravis historical patient pools and forecasted Myasthenia Gravis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Myasthenia Gravis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Myasthenia Gravis Prevalence 
• Age-Specific Myasthenia Gravis Prevalence 
• Gender-Specific Myasthenia Gravis Prevalence 
• Diagnosed and Treatable Cases of Myasthenia Gravis

Visit for more @ Myasthenia Gravis Epidemiological Insights

Myasthenia Gravis Treatment Market 

The Myasthenia Gravis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Myasthenia Gravis market trends by analyzing the impact of current Myasthenia Gravis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Myasthenia Gravis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Myasthenia Gravis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Myasthenia Gravis market in 7MM is expected to witness a major change in the study period 2019-2032.

Myasthenia Gravis Emerging Therapy Assessment

Efgartigimod: Argenx

Efgartigimod is an investigational antibody fragment designed to decrease disease-causing immunoglobulin G (IgG) antibodies and inhibit the IgG recycling process. Results from Phase III clinical trial (ADAPT) showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG). Efgartigimod is under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date

Ravulizumab: Alexion Pharmaceuticals

Ravulizumab is the first and only long-acting C5 complement inhibitor. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Alexion Pharmaceuticals reported positive topline results from a Phase III study evaluating the safety and efficacy of ravulizumab in adults with generalized myasthenia gravis (gMG). The company plans to make regulatory filings in the US, EU & Japan in late 2021 or early 2022, based on P-III results.

Inebilizumab: Horizon Therapeutics

Inebilizumab is a monoclonal antibody that binds to a protein called CD-19, found on the surface of immune B-cells. The therapy was designed to deplete these cells, which play a central role in the progression of autoimmune diseases like MG. In a $3.05 billion deal, Horizon Therapeutics acquired Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune diseases such as myasthenia gravis. The therapy is currently being investigated in people with MG in a Phase III clinical trial that is now recruiting participants in Columbia.

Myasthenia Gravis Key Companies

• Viela Bio
• UCB Pharma
• Momenta Pharmaceuticals
• Sanofi
• Regeneron Pharmaceuticals
• Ra Pharmaceuticals
• Hoffmann-La Roche
• Alexion Pharmaceuticals
• Catalyst Pharmaceuticals
• Harbour BioMed
• Novartis
• Takeda
• DAS Therapeutics
• RemeGen
• Cartesian Therapeutics
• Nanjing IASO Biotherapeutics
• Cabaletta Bio
• CytoDyn
• Ahead Therapeutics
• Toleranzia
• Rallybio

For more information, visit Myasthenia Gravis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Myasthenia Gravis Market Report:

• 10 Years Forecast
• 7MM Coverage 
• Descriptive overview of Myasthenia Gravis, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Myasthenia Gravis epidemiology in the 7MM
• Myasthenia Gravis marketed and emerging therapies 
• Myasthenia Gravis companies
• Myasthenia Gravis market drivers and barriers 

Key Questions Answered in the Myasthenia Gravis Market Report 2032:

• What was the Myasthenia Gravis market share distribution in 2019, and how would it appear in 2032?
• What is the total Myasthenia Gravis market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Myasthenia Gravis market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Myasthenia Gravis market projected to expand at 7MM?

Table of Contents:

1 Myasthenia Gravis Market Key Comprehensive Insights 

2 Myasthenia Gravis Market Report Introduction

3 Competitive Intelligence Analysis for Myasthenia Gravis

4 Myasthenia Gravis Market Analysis Overview at a Glance

5 Executive Summary of Myasthenia Gravis

6 Myasthenia Gravis Epidemiology and Market Methodology

7 Myasthenia Gravis Epidemiology and Patient Population

8 Myasthenia Gravis Patient Journey

9 Myasthenia Gravis Treatment Algorithm, Myasthenia Gravis Current Treatment, and Medical Practices

10 Key Endpoints in Myasthenia Gravis Clinical Trials

11 Myasthenia Gravis Marketed Therapies 

12 Myasthenia Gravis Emerging Therapies

13 Myasthenia Gravis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Myasthenia Gravis

16 Myasthenia Gravis Market Key Opinion Leaders Reviews

18 Myasthenia Gravis Market Drivers

19 Myasthenia Gravis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Myasthenia Gravis Epidemiology 2032

DelveInsight’s “Myasthenia Gravis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Myasthenia Gravis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Myasthenia Gravis Pipeline 2023

“Myasthenia Gravis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myasthenia Gravis market. A detailed picture of the Myasthenia Gravis pipeline landscape is provided, which includes the disease overview and Myasthenia Gravis treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/